Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Longevity Health Holdings has secured a temporary reprieve from Nasdaq delisting, but the clock is ticking as the ...

Sheila Mikhail sold her biotech company in a $4 billion deal a few years ago. Now, after battling cancer, she's on a mission ...

VintaBio presented promising new data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, ...